Navigation Links
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Date:3/3/2008

Company Achieves 2007 Net Income of $13.1 Million

DUBLIN, Calif., March 3 /PRNewswire-FirstCall/ -- SuperGen Inc., (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today reported financial results for the fourth quarter and year ended December 31, 2007.

The Company reported net income for the 2007 fourth quarter of $5.1 million, or $0.09 per fully diluted share, compared with a net loss of $6.3 million, or $0.11 per fully diluted share, for the same prior year period. The Company reported net income for the year ended December 31, 2007 of $13.1 million, or $0.23 per fully diluted share, compared with a net loss of $16.5 million, or $0.31 per fully diluted share, for the same prior year period.

Highlights for 2007 include:

-- Dacogen royalty revenue was $22.3 million compared to $3.4 million for

2006.

-- A major contributor to net income during 2007 was the gain on

disposition of non-core assets including the sale of worldwide rights

for Nipent(R) (pentostatin for injection) and Surface Safe(R),

resulting in a reported gain on sale of products of $33.7 million.

-- The Company closed the year with unrestricted cash, cash equivalents,

and marketable securities totaling approximately $91 million.

"SuperGen has again achieved several significant milestones during 2007 including the start of Phase 1 and Phase 1b clinical trials of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI)," said Dr. James Manuso, President and Chief Executive Officer. "We entered 2008 with a strong financial position. Our lice
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index ... , in particular, drug/device combinations. The current system received a score of 0 (range ... Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , ANNAPOLIS, Md., July 31 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, today announced that, ... of 2-year, 10% unsecured senior convertible notes ("Notes") and common ... $19.3 million. , , In connection with ...
... 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... four patents to the State Intellectual Property Office ... These applications are patents for a ...
... , TOKYO, July 31 R-Tech Ueno, Ltd. ... meeting of the board of directors held on the day and ... The company intends to actively strengthen R&D in the ophthalmologic & ... relevant affiliation, etc. with external entities. , , ...
Cached Biology Technology:PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 2China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 3R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... The 2009 American Society for Microbiology Public ... reporters Michael Berens and Ken Armstrong for their ... (MRSA) in Washington State hospitals. The series, entitled ... the spread of epidemics such as MRSA infection ...
... diseases that starve eye tissue and nerves of oxygen ... researchers at Oak Ridge National Laboratory, the University of ... technique uses a new class of smart prosthetic implants ... oxygen because of restricted blood flow. This condition occurs ...
... high among people born in Scotland or Ireland compared with ... Research, conducted by the University of Edinburgh and the Office ... but living in England and Wales had similar ... The findings showed too that people born in parts of ...
Cached Biology News:Seattle Times reporters win ASM public communications award 2ORNL, Southern Cal set sights on preventing blindness 2Scots and Irish at greater risk of drink-related death, study shows 2
... is a post-translational modification that plays ... including immune regulation, inflammation, cell-to-cell adhesion, ... developed two lectin based Glycoprotein Isolation ... Germ Agglutinin (WGA), that allow isolation ...
... maleimide activated carrier proteins to simplify ... Maleimide Activated Carrier Proteins are commonly ... with a heterobifunctional cross-linker (Sulfo-SMCC). This ... carrier protein. Thus allowing the ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Cell Culture Flask, nontreated polystyrene...
Biology Products: